Kringle PharmaKringle Pharma,Inc.4884東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP
It lost about ¥1259 for every ¥100 of sales at the operating level. Revenue changed -9.8% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -11.4% | —× | — |
| 2022 | — | —× | -11.4% | —× | — |
| 2023 | — | —× | -29.3% | —× | — |
| 2024 | — | —× | -28.1% | —× | — |
| 2025 | — | —× | -37.9% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Sep 2021 | FY ending Sep 2022 | FY ending Sep 2023 | FY ending Sep 2024 | FY ending Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 290 | 392 | 69 | 80 | 72 |
| Cost of revenue | 72 | 88 | 0 | 0 | 0 |
| Gross profit | 218 | 303 | 69 | 80 | 72 |
| SG&A | 576 | 730 | 958 | 898 | 982 |
| Operating income | -358 | -426 | -889 | -818 | -909 |
| Pretax income | -300 | -330 | -853 | -755 | -915 |
| Income tax | 1 | 1 | 1 | 1 | 2 |
| Net income attributable to owners | -301 | -332 | -854 | -756 | -916 |
| Operating margin | -123.5% | -108.8% | -1283.4% | -1021.9% | -1259.4% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Sep 2021 | FY ending Sep 2022 | FY ending Sep 2023 | FY ending Sep 2024 | FY ending Sep 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥2.14B | ¥2.5B | ¥1.76B | ¥1.82B | ¥991.3M |
| Total assets | ¥2.64B | ¥3.21B | ¥2.62B | ¥2.76B | ¥2.08B |
| Net assets | ¥2.51B | ¥2.79B | ¥2.02B | ¥2.11B | ¥1.31B |
| Share capital | ¥51.8M | ¥59.9M | ¥97.5M | ¥11.3M | ¥64.2M |
| Current assets | ¥2.63B | ¥3.21B | ¥2.62B | ¥2.76B | ¥2.06B |
| Current liabilities | ¥127.2M | ¥162.8M | ¥209.1M | ¥128.2M | ¥109.3M |
| Total liabilities | ¥129.5M | ¥419.5M | ¥597M | ¥648.9M | ¥770.1M |
| Equity attributable to owners of parent | ¥2.51B | ¥2.79B | ¥2.01B | ¥2.09B | ¥1.28B |
| Retained earnings | -¥301.2M | -¥331.8M | -¥1.19B | -¥756.5M | -¥1.67B |
| Treasury stock | -¥45K | -¥75K | -¥75K | -¥106K | -¥147K |
EDINET (FSA Japan)
有価証券報告書－第24期(2024/10/01－2025/09/30)
EDINET (FSA Japan)
有価証券報告書－第23期(2023/10/01－2024/09/30)
EDINET (FSA Japan)
有価証券報告書－第22期(2022/10/01－2023/09/30)
EDINET (FSA Japan)
有価証券報告書－第21期(令和3年10月1日－令和4年9月30日)
EDINET (FSA Japan)
有価証券報告書－第20期(令和2年10月1日－令和3年9月30日)
EDINET (FSA Japan)
有価証券報告書－第19期(令和1年10月1日－令和2年9月30日)
Extracted from XBRL: 36 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.